Skip to main content

2 January 2014

Smiths Medical has gained a key US Food and Drug Administration (FDA) approval for a customisable infusion system that helps maintain effective epidural analgesia during labour and delivery or with post-operative pain management.

The FDA 510(k) clearance allows Smiths Medical to market its CADD®-Solis pain management system version 3.0 with Programmed Intermittent Bolus (PIB) and Patient Controlled Analgesics (PCA) delivery in the United States.

PIB medication delivery, using the CADD®-Solis v3.0, consistently administers programmed intermittent boluses (doses) that can be supplemented by the patient, improving pain relief and reducing the need for clinical interventions.

The CADD®-Solis ambulatory infusion system, designed for nurses, anesthesiologists, pharmacists and other hospital personnel, is a state-of-the-art system that meets industry recognised standards for advanced error-reduction features in PCA pumps.

General media enquiries

Contact our global media and communications team at:

Tom Steiner

Tom Steiner

Head of External Communications

+44 (0) 20 7004 1600

Email Arrow right icon

Please note – the press team can only answer enquiries from accredited members of the press.

Related articles

Earth View

Smiths Group plc – Q3 Trading Update

Find out more Call to action arrow icon
Dubai Aviation Engineering Projects Has Signed A Deal With Smiths Detection 1 Copy

Smiths Detection awarded contract to provide checkpoint screening technology for Dubai International Airport

Read our latest company news as Smiths Detection is awarded a new contract from DAEP to provide checkpoint screening technology for Dubai International Airport

Find out more Call to action arrow icon
Davinci Gen V Gen Front View[36]

Smiths Interconnect launches ‘DaVinci Gen V’ next-generation test socket

Read our latest company news as Smiths Interconnect launches ‘DaVinci Gen V’ next-generation test socket

Find out more Call to action arrow icon
Sign up for updates Call to action arrow icon